Xilia-M 2 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, acts by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The prolonged-release formulation ensures a steady plasma concentration, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Xilia-M 2 Forte is prescribed as an adjunct to diet and exercise to achieve better glycemic control in patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia. Contraindications include severe renal impairment, metabolic acidosis, and conditions predisposing to hypoxia. Caution is advised in patients with hepatic dysfunction or cardiovascular disease. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. This combination therapy offers a synergistic approach by targeting multiple pathophysiological defects in type 2 diabetes, facilitating improved glycemic management and reducing the risk of diabetes-related complications.